Table 2.
The relationship of b‐FGF, endostatin and various clinical and pathologic parameters of osteosarcoma
| bFGF expression (cases) | Endostatin expression (cases) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| − | + | ++ | +++ | P values | − | + | ++ | +++ | P values | |
| Group | ||||||||||
| CD34 | ||||||||||
| − | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | ||
| + | 2 | 1 | 2 | 0 | 2 | 1 | 1 | 1 | ||
| ++ | 4 | 0 | 6 | 8 | 0 | 1 | 2 | 5 | ||
| +++ | 0 | 0 | 5 | 1 | 0.130 | 0 | 0 | 1 | 5 | 0.031 |
| Tissue differentiation | ||||||||||
| well differentiated | ||||||||||
| 4 | 1 | 3 | 2 | 2 | 2 | 5 | 1 | |||
| poorly differentiated | ||||||||||
| 2 | 0 | 10 | 8 | 0.054 | 0 | 0 | 10 | 10 | 0.004** | |
| Tumor diameter | ||||||||||
| ≥8 cm | 3 | 1 | 8 | 5 | 2 | 0 | 8 | 7 | ||
| <8 cm | 3 | 0 | 5 | 5 | 0.771 | 0 | 2 | 7 | 4 | 0.629 |
| Pre‐operative chemotherapy | ||||||||||
| Yes | 3 | 1 | 4 | 4 | 2 | 0 | 7 | 3 | ||
| No | 3 | 0 | 9 | 6 | 0.635 | 0 | 2 | 8 | 8 | 0.264 |
| Ages (years) | ||||||||||
| ≥16 | 4 | 1 | 10 | 10 | 2 | 2 | 13 | 8 | ||
| <16 | 2 | 0 | 3 | 0 | 0.090 | 0 | 0 | 2 | 3 | 0.188 |
| ALP | ||||||||||
| ≥150 u/l | 3 | 0 | 7 | 3 | 1 | 1 | 3 | 8 | ||
| <150 u/l | 3 | 1 | 6 | 7 | 0.460 | 1 | 1 | 12 | 3 | 0.069 |
| Enneking staging | ||||||||||
| Ia | 0 | 0 | 3 | 1 | 0 | 0 | 4 | 0 | ||
| Ib | 2 | 1 | 4 | 1 | 2 | 0 | 3 | 4 | ||
| IIa | 0 | 0 | 1 | 2 | 0 | 0 | 2 | 1 | ||
| IIb | 3 | 0 | 4 | 5 | 0 | 0 | 5 | 6 | ||
| III | 1 | 0 | 1 | 1 | 0.302 | 0 | 2 | 1 | 0 | 0.610 |
| Metastasis | ||||||||||
| No | 5 | 1 | 12 | 9 | 2 | 0 | 14 | 1 | ||
| Yes | 1 | 0 | 1 | 1 | 0.796 | 0 | 2 | 1 | 0 | 0.036* |
| Postoperative survival | ||||||||||
| ≥1 year | 5 | 1 | 11 | 8 | 2 | 1 | 12 | 10 | ||
| <1 year | 1 | 0 | 2 | 2 | 0.766 | 0 | 1 | 3 | 1 | 0.426 |
*
P < 0.05;
**
P < 0.01.